3Allred AJ, Bowen C J, Park JW, et al. Ehrombopag increases plasma rosuvastatin exposure in healthy volunteers [J]. Br J Clin Pharmaco, 2011, 172(2):321 - 329.
4Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome 17450 2D6 (CYP2D6) genotype [J]. Clin Pharmacol Ther, 2012,91(2):321- 326.
5Wilke RA, Ramsey LB, Johnson SG, et al. The Clinical Phar- macogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy [J]. Clin Pharma- col Ther, 2012,92(1):112-117.
6Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysisin Han Chinese [J]. Pharmacoge- nomics, 2010,11(3): 349-356.
7Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse drug reactions and pre- ventability of adverse drug reactions-A meta-analysis [J]. PLoS ONE, 2012,3(7):1-9.
